Skip to main content
Psychedelic State(s) of America
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Onlinelibrary Wiley

Published November 7, 2026

Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for ...

Read the full story at Onlinelibrary Wiley

In psychedelic research, pre-trial expectations are often described as part of the “set” (Hartogsohn 2016) and can significantly influenceboth.

Post on X

Share this story

Share on XShare on LinkedInShare on FacebookShare on WhatsAppShare on Signal

Surfaced by this Google Alert

  • Psychedelics